Lb Pharmaceuticals earnings release, August 11, 2026
LB Pharmaceuticals Reports Second
Quarter 2026 Financial Results and Provides Corporate Update
Announced accelerated timing of topline data readout from the pivotal
Phase 3
NOVA-2 trial of
LB-102 in schizophrenia in the first half of 2027
Announced plans for pipeline expansion of
LB-102 into new neuropsychiatric indications with strong mechanistic rationale and validating clinical and real-world experience from amisulpride
Cash, cash equivalents, and marketable securities of $327.8 million as of June 30, 2026, and proceeds from recent $150.0 million private placement to fund pipeline expansion, expected to fund operations beyond Q2 2029, through multiple clinical milestones
NEW YORK, August 11, 2026 (GLOBE NEWSWIRE) – LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain diseases, today announced financial results for the second quarter ended on June 30, 2026 and provided a corporate update.
“We are taking meaningful steps to maximize the full potential of
LB-102, leveraging clinically validated biology with purposeful innovation as the foundation for an expanded pipeline,” said Heather Turner, Chief Executive Officer of LB Pharmaceuticals. “We recently announced a private placement of
$150 million with participation from new and existing investors to expand the development of
LB-102 into new indications where unmet needs align with the emerging clinical profile of
LB-102.
We are looking forward to our first pivotal trial readout and recently announced that, based on enrollment in our pivotal
NOVA-2 trial in schizophrenia being more rapid than expected, we now project topline data readout in the first half of 2027, ahead of our prior guidance, and plan to schedule a pre-NDA meeting with the FDA soon thereafter in the second half of 2027.
We are well positioned to advance multiple clinical programs and continue to expect topline data from our Phase 2 trial of
LB-102 in bipolar depression in the first quarter of 2028 as well as data from our
Phase 2 trial of
LB-102 in adjunctive MDD in the first half of 2029.”
Second Quarter 2026 and Recent
Highlights
The Company’s lead asset,
LB-102, is a novel benzamide in late-stage clinical development for psychosis and mood disorders.
LB-102 has the opportunity to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.
LB-102 in Schizophrenia
LB-102 in Mood Disorders: Bipolar Depression and Adjunctive Treatment of MDD
Corporate Updates
Financial Results for the Three Months Ended June 30, 2026
Financial Results for the Six Months Ended
June 30, 2026
About
LB-102
LB-102 is a novel, once-daily, orally administered investigational small molecule and potential first benzamide antipsychotic in the United States for the treatment of neuropsychiatric disorders. A methylated derivative of amisulpride, a widely used antipsychotic outside the United States, LB-102 was developed to retain amisulpride’s benefits while addressing its limitations. LB-102 is a potent and selective antagonist of D2, D3, and 5-HT7 receptors with few off-target effects and broad therapeutic potential across psychosis and mood disorders. In early 2025, LB Pharmaceuticals announced positive data from a four-week placebo-controlled, double-blinded, Phase 2 trial in patients with acute schizophrenia. In this trial, LB-102 demonstrated statistically significant benefit versus placebo at all doses studied, including rapid onset of effect at week 1 and sustained benefit through the endpoint of the trial, a potentially class-leading safety profile with low rates of EPS (including akathisia), minimal sedation and few GI side effects, alongside effects on negative symptoms and cognitive performance. These data underscore
LB-102’s potential to address multiple dimensions of neuropsychiatric illness. The pivotal Phase 3
NOVA-2 trial of
LB-102 for acute schizophrenia and the Phase 2
ILLUMINATE-1 trial of
LB-102 for bipolar 1 depression are ongoing, and a
Phase 2 trial of
LB-102 in adjunctive treatment of MDD is planned. The Company is also pursuing additional expansion opportunities for
LB-102 including predominantly negative symptoms of schizophrenia, Alzheimer’s disease psychosis and agitation, as well as other neuropsychiatric diseases.
About LB Pharmaceuticals
LB Pharmaceuticals is a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate,
LB-102, which the Company believes has the opportunity to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.
LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a balanced clinical activity and tolerability profile that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of a broad range of neuropsychiatric diseases.
Financial statements
Income Statement
Three Months Ended June 30, — (Unaudited) (in thousands)
| Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| Operating expenses | Research and development | 44,146 | 2,421 | 58,791 | 5,842 |
| Operating expenses | General and administrative | 9,769 | 2,438 | 17,228 | 5,446 |
| Operating expenses | Total operating loss | -53,915 | -4,859 | -76,019 | -11,288 |
| Non-operating income | Interest income | 2,974 | 177 | 5,824 | 413 |
| Non-operating income | Realized gain on sale of marketable securities, net | 119 | |||
| Non-operating income | (Loss) gain on change in fair value of derivative instruments | -662 | -189 | -462 | 579 |
| Non-operating income | Total non-operating income (loss) | 2,312 | -12 | 5,362 | 1,111 |
| Non-operating income | Loss before income tax | -51,603 | -4,871 | -70,657 | -10,177 |
| Non-operating income | Net loss | -51,603 | -4,871 | -70,657 | -10,177 |
| Non-operating income | Net loss per share, basic and diluted | -1.71 | -13.58 | -2.42 | -28.36 |
| Non-operating income | Weighted average shares outstanding used in calculating net loss per share, basic and diluted | 30,137,733 | 358,811 | 29,194,955 | 358,794 |
Balance Sheet
(In thousands) (in thousands)
| As of – June 30, 2026 | As of – December 31, 2025 | |
|---|---|---|
| Cash, cash equivalents and marketable securities | 327,790 | 295,213 |
| Total assets | 361,692 | 312,934 |
| Total liabilities | 29,345 | 11,624 |
| Total stockholders’ equity | 332,347 | 301,310 |
Full release
Cautionary Note Regarding Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,”
“design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,”... (truncated)ments other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning the expected clinical development and regulatory pathway and therapeutic benefits of
LB-102; the design, objectives, initiation, timing, progress and results of clinical trials of
LB-102, including the pivotal Phase 3
NOVA-2 trial in acute schizophrenia, our open label trial
(NOVA-3), the Phase 2
ILLUMINATE-1 trial in bipolar 1 depression and the
Phase 2 trial for the adjunctive treatment of MDD; the Company’s plan to pursue any additional indications including negative symptoms of schizophrenia and Alzheimer’s disease psychosis/agitation; anticipated cash runway beyond the second quarter of 2029; continued advancement of
LB-102 and the Company’s portfolio. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: the Company’s limited operating history and historical losses; the Company’s ability to raise additional funding to complete the development and any commercialization of
LB-102; the Company’s dependence on the success of its lead product candidate,
LB-102; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidate; the early stages of clinical development of the Company’s lead product candidate,
LB-102; any undesirable side effects or other properties of the Company’s product candidate; that the Company may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; the
Company’s ability to obtain, maintain and protect its intellectual property; and the Company’s dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.
These and other risks are described more fully in the section titled “Risk Factors” in the
Company’s Quarterly Report on Form
10-Q for the quarter ended March 31, 2026 and its other documents to be subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Media and Investor Contact
:
Ellen Rose erose@lbpharma.us
LB Pharmaceuticals Inc
Condensed Statements of Operations
(in thousands, except share and per share data)
(Unaudited)
LB Pharmaceuticals Inc
Unaudited Condensed Balance Sheets
(In thousands)